A 3-year progress report on the implementation of LAAM in the United States.

@article{Rawson1998A3P,
  title={A 3-year progress report on the implementation of LAAM in the United States.},
  author={Richard A Rawson and Ariel Hasson and Agnes M. Huber and Michael J. McCann and W Emily Ling},
  journal={Addiction},
  year={1998},
  volume={93 4},
  pages={533-40}
}
AIMS LAAM, a long-acting opioid agonist, was approved by the US Food and Drug Administration in 1993 for use in licensed narcotic treatment programs. These programs have the exclusive authority in the United States to dispense methadone and LAAM for the treatment of opiate dependence. The purpose of this report is to describe the course of LAAM's implementation and to document some of the factors that have influenced the time course and extent of this process. DESIGN Narcotic treatment… CONTINUE READING